History

Increased the capital to ImmunAdd Inc.
Awarded Top 5% in the 11th Corporate Governance Evaluation (Listed Companies category) and simultaneously selected as Top 10 Best among non-financial electronics listed and OTC companies with a market value exceeding NT$10 billion.
Awarded Top 1% worldwide in the S&P Global Sustainability Assessment, ranking 4th globally in the Diversified Financial Services & Capital Markets category.
On August 11, co-hosted the 2025 Asia-Pacific Biotechn Investment Forum with the Taiwan Stock Exchange and the Taipei Exchange.

Increased the capital to 100% own subsidiaries Diamond I Inc. and Diamond II Inc.
Diamond I increased the capital to StemCyte, a Cayman Islands company.

Invested in Rejuvenate Bio, a U.S. company.
Invested in ImmunAdd Inc.
Invested in Syncell Inc., a British Cayman Islands company.
Increased the capital to StemCyte, a Cayman Islands company.
Diamond Biofund increased its capital to NT$7.493 billion by declaring stock dividends.
Prior to its initial listing, Diamond Biofund increased its capital to NT$8.493 billion though cash injection.
Diamond Biofund underwent IPO on TWSE Main Board on September 19th (TWSE : 6901), as the first publicly listed evergreen biotech venture capital in Taiwan.
Established and increased the capital to 100% owned subsidiaries Diamond I Inc. and Diamond II Inc.

Diamond Biofund listed on TPEx Emerging Stock Board on July 25th (TPEx : 6901), becoming the first publicly trading evergreen biotech venture capital in Taiwan.
Diamond Biofund completed its Emerging Stock Board listing in May 2022.
Diamond Biofund increased its capital to NT$6.350 billion by declaring stock dividends.

Invested in Kendall Capital Partners, a US venture capital firm .
Invested in Bilayer Therapeutics, a US biotech company.
Diamond Biofund increased its capital to NT$6.5 billion by declaring stock dividends.
Diamond Biofund merged subsidiary companies – Jung Jian Investment Co., Ltd., Jing Ying investment Co., Ltd., and Feng Sheng Investment Co., Ltd.
Diamond Biofund split and reduced its capital to establish Jing Ying investment Co., changing its capital to NT$5 billion.

Portfolio company – Oneness Biotech (TPEx : 4743) achieved the largest licensing deal in Taiwan’s biotech new drug history, with upfront and milestone payments totaling US$530 million (approximately NT$15.9 billion).
Portfolio company – Oneness Biotech (TPEx : 4743) conducted a GDR offering, marking the largest overseas fundraising in Taiwan’s biotech history, with a total of approximately US$177 million (approximately NT$5.06 billion).

Portfolio company – Fountain Biopharma (TPEx : 4159) was acquired by Oneness Biotech (TPEx : 4743) via share swap. Diamond Biofund thus acquired shares of Oneness Biotech.

Collaborated with National Chung Hsing University to founded Tetanti Agribiotech Inc.

Portfolio company – Synovel Sciences Inc. was acquired by Fountain Biopharma (TPEx : 4159) via share swap. Diamond Biofund thus acquired shares of Fountain Biopharma.
Invested in EyeYon Medical Ltd., an Israeli company.

Diamond Biofund capital was reduced to NT$4.5 billion and spun-off Sun Biofund Inc.
Invested in Sinew Pharma Inc. (Listed on TPEx in 2017, TPEx : 6634).

Collaborated with Taipei Medical University to establish 3D Global Biotech Inc. (Listed on TPEx in 2020, TPEx : 6808)
Signed an MOU with National Cheng Kung University and National Chung Hsing University to promote entrepreneurship on campuses.
Invested in Theia Medical Technology Inc., a spin-off startup of National Tsing Hua University.
Invested in IOPtima Ltd., an Israeli company (later acquired by Chengdu Kanghong Pharmaceutical Group Co., Ltd. in 2017 (SZSE : 002773)).

Diamond Biofund increased its capital to NT$8.0 billion via a cash capital injection of NT$4.0 billion.
Invested in Enimmune Corp. (Listed on TPEx in 2018, TPEx : 6564).
Invested in Original Biomedicals Co., Ltd. (Listed on TPEx in 2014, TPEx : 6483).
Invested in Genomics BioSci & Tech Co., Ltd. (TPEx : 4195).
Collaborated with Academia Sinica and National Taiwan University to establish Synovel Sciences Inc., which was later acquired by Fountain Biopharma Inc. (TPEx : 4159) via share swap.
Signed an MOU with National Chiao Tung University and National Yang Ming University to promote entrepreneurship on campuses.

Established with an initial capital of NT$3.0 billion, Diamond Biofund is the first-evergreen biotech venture capital in Taiwan.
The founding shareholders include Microbio Group, Fubon Financial, Taishin Holdings, and Ruentex Group.
Diamond Biofund increased its capital to NT$4.0 billion via a cash capital injection of NT$1.0 billion.
Collaborated with Academia Sinica to establish CHO Pharma Inc. (Listed on TPEx in 2017, TPEx : 6586).
Invested in Swissray Global Healthcare Holding Ltd. (Listed on TPEx in 2013, TPEx : 4198).
Invested in StemCyte Inc. and became its second-largest shareholder.